Amani Therapeutics Funding Round

3/24/2026

Venture Equity

$25,000,000

Series A

The company intends to use the funds to expand operations and R&D efforts.

Private & Independent

Biopharmaceutical

40 10th Avenue, 7th Floor
New York, NY 10014
USA

Undisclosed

Driving innovative science to deliver safer and more effective psychiatric treatments to patients -- faster. Amani's lead program, AM-01, is a fixed-dose combination product that includes clozapine and a Phase 3--ready NCE with worldwide rights in-licensed from AstraZeneca. Amani believes AM-01 has the potential to deliver clozapine's unmatched efficacy for patients with schizophrenia while addressing clozapine's most significant safety liability--severe neutropenia--and the burdensome blood-monitoring that limit its use. Clozapine remains the only medication proven to meaningfully improve symptoms in treatment-resistant schizophrenia and to reduce suicide risk in patients with schizophrenia and schizoaffective disorder. Despite its clinical benefits, it is profoundly underutilized due to safety concerns and monitoring requirements.